Lessons from Gilead: Q&A with the CEO of the Bay Area’s newest public biotech

Kronos CEO Norbert Bischofberger, whose company raised more than $250 million in its IPO, talks about the flow of cash into the biotech industry, its "Zoom show" and survival of the fittest.

Click to view original post